Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mebhydrolin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 4/20 | 0.70 |
| ▸ | MAOA known ✓ | P21397 | 4/20 | 0.69 |
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.69 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.68 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebhydrolin SCHEMBL29802 | 0.99 | ADRA2A (1.00) | ALDH1A1GAATSHRADRA2AADRA1A | |
| Mebhydrolin SCHEMBL29808874 | 0.99 | ADRA2A (1.00) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL8038611 | 0.91 | CHRM2 (0.85) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL12938848 | 0.90 | ADRA2A (0.83) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL3716403 | 0.90 | CHRM2 (0.83) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL4130866 | 0.88 | HRH1 (0.82) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL4125370 | 0.88 | CHRM2 (0.81) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL19970051 | 0.88 | CHRM2 (0.80) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL3621165 | 0.88 | HTR6 (0.81) | ALDH1A1GAATSHRADRA2AADRA1A | |
| SCHEMBL24630759 | 0.86 | ADRA2A (0.77) | ALDH1A1GAATSHRADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101121-A1 | DRUG DEMONSTRATING ANXIOLYTIC EFFECT BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES, ITS PHARMACOLOGICAL COMPOUND AND APPLICATION METHOD | Medivation Neurology ,Inc. | 2012-04-26 | — | — | US | disclosed |
| US-20100286188-A1 | MEANS FOR IMPROVING COGNITIVE FUNCTIONS AND MEMORY BASED ON HYDROGENATED PYRIDO(4,3-B)INDOLES (VARIANTS), PHARMACOLOGICAL MEANS BASED THEREON AND METHOD FOR THE USE THEREOF | BACHURIN SERGEY O | 2010-11-11 | — | — | US | disclosed |
| US-20100178277-A1 | METHODS AND COMPOSITIONS FOR STIMULATING CELLS | MEDIVATION NEUROLOGY, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | MEDIVATION NEUROLOGY, INC. | 2010-04-22 | — | — | US | disclosed |
| EP-2175724-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY | Medivation Neurology, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-2161995-A1 | A DRUG DEMONSTRATING ANXIOLYTIC EFFECT BASED ON HYDROGENATED PYRIDO (4, 3-B) INDOLES, ITS PHARMACOLOGICAL COMPOUND AND APPLICATION METHOD | Medivation Neurology, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100029706-A1 | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS | Edison Parmaceuticals, Inc. a Delaware Corporation (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010014758-A1 | USE OF HYDROGENATED PYRIDO[4,3-B] INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS | EDISON PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2008051599-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I. A. DIMEBON AND DOLEPEZIL | MEDIVATION NEUROLOGY, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008036400-A2 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | MEDIVATION, INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007087425-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | MEDIVATION NEUROLOGY,INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070179174-A1 | Methods and compositions for slowing aging | MEDIVATION, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007041697-A2 | HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE | MEDIVATION, INC. (GB) | 2007-04-12 | — | — | WO | disclosed |
| EP-1692131-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005055951-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178277-A1 | METHODS AND COMPOSITIONS FOR STIMULATING CELLS | BAD, NFATC1, HDGF | GAA 3565/4885ADRA2A 2192/4885ADRA1A 2123/4885 |
| US-20100029706-A1 | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS | SHMT2, PRDX5, TXN2 | GAA 2821/4885ADRA2A 1342/4885ADRA1A 1541/4885 |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | GAA 1553/4885ADRA2A 553/4885ADRA1A 470/4885 |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | SLC6A3, DBH, GRIN3B | GAA 3704/4885ADRA2A 976/4885ADRA1A 845/4885 |
| US-20070179174-A1 | Methods and compositions for slowing aging | PRDX5, HMOX1, SHMT2 | GAA 1920/4885ADRA2A 1913/4885ADRA1A 1694/4885 |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | GAA 486/4885ADRA2A 3695/4885ADRA1A 3232/4885 |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | HPD, KYNU, IDO1 | GAA 3887/4885ADRA2A 2203/4885ADRA1A 1271/4885 |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | HTT, NLN, SMN1; SMN2 | GAA 1734/4885ADRA2A 3518/4885ADRA1A 2750/4885 |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | GAA 486/4885ADRA2A 3695/4885ADRA1A 3232/4885 |
| US-20120101121-A1 | DRUG DEMONSTRATING ANXIOLYTIC EFFECT BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES, ITS PHARMACOLOGICAL COMPOUND AND APPLICATION METHOD | TPH1, TPH2, HTR3B | GAA 3311/4885ADRA2A 151/4885ADRA1A 196/4885 |
| US-20100286188-A1 | MEANS FOR IMPROVING COGNITIVE FUNCTIONS AND MEMORY BASED ON HYDROGENATED PYRIDO(4,3-B)INDOLES (VARIANTS), PHARMACOLOGICAL MEANS BASED THEREON AND METHOD FOR THE USE THEREOF | HTR6, TPH1, IDO1 | GAA 1700/4885ADRA2A 718/4885ADRA1A 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.